Planned Parenthood has expanded its advance-provision abortion pill initiative to allow procurement prior to pregnancy, while the U.S. Food and Drug Administration has launched a safety review of the abortion drug mifepristone. These dual developments take place amid ongoing legal and political conflicts over medication access, drawing intense scrutiny from pro-life organizations advocating for greater medical safeguards and resistance from abortion-rights groups. At the heart of these actions lies a fundamental debate regarding the safety, normalization, and regulation of chemical procedures versus the protection of maternal health and unborn life.